Enliven Therapeutics (NASDAQ:ELVN) Director J. Scott Garland Sells 13,000 Shares of Company Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director J. Scott Garland sold 13,000 shares of the stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $46.67, for a total value of $606,710.00. Following the transaction, the director owned 13,000 shares in the company, valued at $606,710. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Enliven Therapeutics Stock Performance

NASDAQ:ELVN traded down $1.50 during mid-day trading on Monday, reaching $45.47. The stock had a trading volume of 821,495 shares, compared to its average volume of 1,258,190. The firm has a 50 day moving average price of $55.23 and a two-hundred day moving average price of $47.39. The stock has a market capitalization of $3.33 billion, a P/E ratio of -27.23 and a beta of 0.24. Enliven Therapeutics, Inc. has a one year low of $14.78 and a one year high of $62.32.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10). Research analysts forecast that Enliven Therapeutics, Inc. will post -1.75 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms recently commented on ELVN. JonesTrading increased their target price on shares of Enliven Therapeutics from $45.00 to $70.00 and gave the company a “buy” rating in a report on Monday, June 29th. Morgan Stanley assumed coverage on shares of Enliven Therapeutics in a research note on Friday. They issued an “overweight” rating and a $70.00 price target for the company. Guggenheim cut their price target on shares of Enliven Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Wall Street Zen cut Enliven Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Finally, Mizuho lifted their price objective on Enliven Therapeutics from $62.00 to $73.00 and gave the stock an “outperform” rating in a report on Tuesday, August 18th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Enliven Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $74.44.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. KBC Group NV bought a new position in Enliven Therapeutics in the 1st quarter worth $38,000. State of Wyoming purchased a new position in shares of Enliven Therapeutics during the 2nd quarter worth approximately $96,000. FNY Investment Advisers LLC purchased a new position in shares of Enliven Therapeutics during the 2nd quarter worth approximately $126,000. Seven Fleet Capital Management LP bought a new position in shares of Enliven Therapeutics in the 4th quarter worth approximately $180,000. Finally, Royal Bank of Canada raised its position in shares of Enliven Therapeutics by 345.0% in the 1st quarter. Royal Bank of Canada now owns 5,424 shares of the company’s stock worth $212,000 after acquiring an additional 4,205 shares in the last quarter. 95.08% of the stock is owned by hedge funds and other institutional investors.

About Enliven Therapeutics

Enliven Therapeutics, Inc (NASDAQ: ELVN) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company seeks to develop therapies designed to address significant unmet needs in oncology, with an emphasis on targeted treatments that may offer improved efficacy, safety, or durability.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for patients with chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for the treatment of HER2-driven cancers.